What is androgen deprivation therapy (ADT)?
Androgen deprivation therapy, or ADT, is the primary treatment for advanced prostate cancer. ADT reduces blood levels of testosterone, a primary growth factor for prostate cancer, by up to 95% and estrogen levels approximately 75%.4 ADT is accomplished either surgically by removal of the testes, or chemically by treatment with luteinizing hormone-releasing hormone (LHRH) agents. LHRH agents work by shutting off luteinizing hormone secretion by the pituitary gland, which stops testosterone production by the testes. Examples of commercially marketed LHRH agents are Lupron Depot® (leuprolide acetate for depot suspension), Decapeptyl® (triptorelin pamoate for depot suspension), Zoladex® (goserelin acetate implant) and Eligard® (leuprolide acetate for injectable suspension).